Drug class
Irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor; historical antineoplastic small molecule
Mechanism of action
Irreversibly inhibits EGFR kinase, including mutant EGFR exon 20 insertion variants, reducing downstream oncogenic signalling. The drug had an accelerated US approval for EGFR exon 20 insertion-mutated NSCLC, but that indication was withdrawn in July 2024 after confirmatory evidence did not verify clinical benefit.
General use cases
- Historical US indication: treatment of adults with locally advanced or metastatic EGFR exon 20 insertion-mutated non-small-cell lung cancer (NSCLC) whose disease had progressed on or after platinum-based chemotherapy. The US approval was withdrawn 15 July 2024; do not present this as a current US-authorised treatment.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
